Literature DB >> 5234586

Lysosomes in type II glycogenosis. Changes during administration of extract from Aspergillus niger.

G Hug, W K Schubert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 5234586      PMCID： PMC2107106          DOI： 10.1083/jcb.35.1.c1

Source DB:  PubMed          Journal:  J Cell Biol        ISSN： 0021-9525            Impact factor:   10.539


× No keyword cloud information.
  7 in total

1.  The action of an amyloglucosidase of Aspergillus niger on starch and malto-oligosaccharides.

Authors:  J H PAZUR; T ANDO
Journal:  J Biol Chem       Date:  1959-08       Impact factor: 5.157

2.  AN ELECTRON MICROSCOPIC AND BIOCHEMICAL STUDY OF TYPE II GLYCOGENOSIS.

Authors:  P BAUDHUIN; H G HERS; H LOEB
Journal:  Lab Invest       Date:  1964-09       Impact factor: 5.662

3.  Tissue fractionation studies. 16. Intracellular distribution and properties of alpha-glucosidases in rat liver.

Authors:  N LEJEUNE; D THINES-SEMPOUX; H G HERS
Journal:  Biochem J       Date:  1963-01       Impact factor: 3.857

4.  Diseases of glycogen storage with special reference to the cardiac type of generalized glycogenosis.

Authors:  P A DI SANT'AGNESE
Journal:  Ann N Y Acad Sci       Date:  1959-02-06       Impact factor: 5.691

5.  Menghini needle biopsy of the liver.

Authors:  R HONG; W K SCHUBERT
Journal:  Am J Dis Child       Date:  1960-07

6.  The liver in generalized glycogen storage disease. Light microscopic observations.

Authors:  A J McAdams; H E Wilson
Journal:  Am J Pathol       Date:  1966-07       Impact factor: 4.307

7.  alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe's disease).

Authors:  H G HERS
Journal:  Biochem J       Date:  1963-01       Impact factor: 3.857
  7 in total
  18 in total

Review 1.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

2.  Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures.

Authors:  H Isaacs; N Savage; M Badenhorst; T Whistler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-09       Impact factor: 10.154

3.  Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.

Authors:  J M Van den Hout; A J Reuser; J B de Klerk; W F Arts; J A Smeitink; A T Van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

4.  Pinocytosis of diphtheria toxin by different types of human cells cultured in vitro.

Authors:  F Paradisi
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

5.  Fine structural aspects of the mobilization of hepatic glycogen. II. Inhibition of glycogen breakdown.

Authors:  O B Kotoulas; J Ho; F Adachi; B I Weigensberg; M J Phillips
Journal:  Am J Pathol       Date:  1971-04       Impact factor: 4.307

6.  The effect of diphtheria toxin on primary cell cultures of the adult human liver.

Authors:  F Paradisi; A Trapani; L Graziano
Journal:  Experientia       Date:  1974-08-15

7.  Latency of endogenous and exogenous lysosomal glucosidases.

Authors:  J B Lloyd
Journal:  Biochem J       Date:  1969-12       Impact factor: 3.857

8.  The genetic mismanagement of complex lipid metabolism.

Authors:  R O Brady
Journal:  Bull N Y Acad Med       Date:  1971-02

9.  Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells.

Authors:  A T van der Ploeg; P A Bolhuis; R A Wolterman; J W Visser; M C Loonen; H F Busch; A J Reuser
Journal:  J Neurol       Date:  1988-09       Impact factor: 4.849

10.  The symptomatology, morphology and biochemistry of glycogenosis type II (Pompe) in the adult.

Authors:  G K Schlenska; R Heene; G Spalke; D Seiler
Journal:  J Neurol       Date:  1976-06-14       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.